by Rithea Leang, Naw Htee Khu, Mavuto Mukaka et al.
BMC Medicine, 2016 14:171 – Published: 27 October 2016
In 2012, the World Health Organization recommended the addition of single low-dose primaquine (SLDPQ, 0.25 mg base/kg body weight) to artemisinin combination therapies to block the transmission of Plasmodium falciparum without testing for glucose-6-phosphate dehydrogenase deficiency. The targeted group was non-pregnant patients aged ≥ 1 year (later changed to ≥ 6 months) with acute uncomplicated falciparum malaria, primarily in countries with artemisinin-resistant P. falciparum (ARPf). No dosing regimen was suggested, leaving malaria control programmes and clinicians in limbo. Therefore, the authors designed a user-friendly, age-based SLDPQ regimen for Cambodia, the country most affected by ARPf.